Video

Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency

Author(s):

Saro Arakelians, PharmD

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:

  • For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
  • Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
  • Chronic immune thrombocytopenia (ITP) in adults.

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Image credit: Photo18@desing | stock.dobe.com
Related Content
Red blood cells | Image Credit: © fotogurmespb - stock.adobe.com
May 15th 2025

Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Microscopic cellular structure of chronic lymphocytic leukemia | Image Credit: ©AI Photo Stock - stock.adobe.com
May 15th 2025

Real-World Study Shows Comparable Survival Outcomes With First-Line Ibrutinib in High-Risk and Non-High-Risk CLL/SLL

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Psilocybin -- Image credit: TaylerDerden | stock.adobe.com
May 15th 2025

The Promise of Psilocybin-Assisted Therapy for Opioid Use Disorder

Craig Kimble, PharmD, MBA, MS, BCACP, TTS Alberto Coustasse, DrPH, MD, MBA, MPH
X-ray image depicting a migraine -- Image credit: peterschreiber.media | stock.adobe.com
May 15th 2025

FDA Approves Brekiya, First and Only DHE Autoinjector, for Acute Treatment of Migraine, Cluster Headaches

Gillian McGovern, Associate Editor